MedTrace Logo

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

NCT06761911 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-01-07

No results posted yet for this study

Summary

The goal of this clinical trial is to explore the real-world Chinese relapsed/refractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are:

To evaluate the efficacy and toxicity of BV-containing regimen in relapsed/refractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.

Conditions

  • Hodgkin Lymphoma (Category)

Interventions

DRUG

Brentuximab Vedotin (Bv)

1.2mg/kg/2w or 1.8mg/kg/3w

DRUG

Sintilimab

200mg/3w

DRUG

Tislelizumab

200mg/3w

DRUG

Bendamustine

90mg/m2/3w

Sponsors & Collaborators

  • Xiuhua Sun

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-31
Primary Completion
2025-12-17
Completion
2026-01-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06761911 on ClinicalTrials.gov